Published in Nanomedicine (Lond) on February 01, 2014
Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 2.77
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 1.55
Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials (2007) 1.49
Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials (2012) 1.39
Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials (2006) 1.32
Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials (2007) 1.29
Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology (2008) 1.27
Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials (2003) 1.27
Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials (2011) 1.25
The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials (2006) 1.21
PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res (2003) 1.20
TIP30 deficiency increases susceptibility to tumorigenesis. Cancer Res (2003) 1.20
Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res (2013) 1.20
Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. MAbs (2012) 1.19
Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials (2009) 1.18
TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression. Hum Pathol (2006) 1.16
Decreased TIP30 expression promotes tumor metastasis in lung cancer. Am J Pathol (2009) 1.16
TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. Cancer Res (2008) 1.15
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials (2008) 1.14
Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A (2009) 1.13
Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol (2009) 1.12
Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials (2013) 1.12
Role of osteopontin in induction of monocyte chemoattractant protein 1 and macrophage inflammatory protein 1beta through the NF-kappaB and MAPK pathways in rheumatoid arthritis. Arthritis Rheum (2009) 1.11
Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev (2012) 1.11
Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma. Clin Cancer Res (2008) 1.09
Paclitaxel drug delivery systems. Expert Opin Drug Deliv (2013) 1.09
Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology (2008) 1.09
Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials (2010) 1.08
Identification of a novel functional domain of ricin responsible for its potent toxicity. J Biol Chem (2011) 1.08
Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. Biomaterials (2008) 1.07
Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res (2008) 1.07
Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem (2013) 1.06
Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice. Clin Cancer Res (2009) 1.05
DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm (2010) 1.05
In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules (2006) 1.04
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology (2006) 1.03
EGFL6 promotes endothelial cell migration and angiogenesis through the activation of extracellular signal-regulated kinase. J Biol Chem (2011) 1.03
In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials (2005) 1.02
Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A (2006) 1.01
Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials (2009) 1.01
Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials (2012) 1.01
Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem (2007) 1.00
Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release (2013) 1.00
In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res (2008) 1.00
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials (2008) 1.00
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood (2009) 1.00
Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab. J Biol Chem (2013) 0.99
A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother (2009) 0.98
Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials (2012) 0.97
Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. Biochem Biophys Res Commun (2008) 0.97
Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials (2012) 0.96
Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials (2010) 0.94
Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci U S A (2004) 0.93
Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum (2008) 0.93
Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm (2011) 0.93
Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J Colloid Interface Sci (2005) 0.93
Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer. Tumour Biol (2014) 0.93
EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials (2011) 0.93
Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials (2007) 0.93
Increased expression of iASPP, regulated by hepatitis B virus X protein-mediated NF-κB activation, in hepatocellular carcinoma. Gastroenterology (2010) 0.92
Self-assembled nanoparticles of poly(lactide)--Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm (2006) 0.92
Cancer immunotherapy using in vitro genetically modified targeted dendritic cells. Cancer Res (2008) 0.92
Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. J Colloid Interface Sci (2004) 0.91
Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond) (2010) 0.91
Development of SM5-1-conjugated ultrasmall superparamagnetic iron oxide nanoparticles for hepatoma detection. Biochem Biophys Res Commun (2008) 0.91
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res A (2010) 0.91
The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials (2011) 0.90
Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci (2010) 0.90
Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res (2013) 0.90
Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm (2010) 0.90
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials (2010) 0.90
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials (2011) 0.89
Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization. Cancer Res (2013) 0.89
Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm (2007) 0.89
Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J Control Release (2002) 0.89
Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting β-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol Life Sci (2013) 0.88
In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials (2007) 0.88
The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials (2011) 0.88
Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int J Pharm (2011) 0.88
Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients. Int J Cancer (2013) 0.87
Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials (2011) 0.87
Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. Int J Nanomedicine (2012) 0.87
Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine (Lond) (2012) 0.87
Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale (2013) 0.87
Folic acid-functionalized two-photon absorbing nanoparticles for targeted MCF-7 cancer cell imaging. Chem Commun (Camb) (2011) 0.86
Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm (2010) 0.86
Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs (2011) 0.86
Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice. J Immunol (2013) 0.86
Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J Immunol (2009) 0.86
Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. Blood (2010) 0.85
Pharmaceutical stability aspects of nanomedicines. Nanomedicine (Lond) (2009) 0.85
Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One (2012) 0.85
Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res (2010) 0.85
A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett (2010) 0.84
DRB genotyping in cynomolgus monkeys from China using polymerase chain reaction -sequence-specific primers. Hum Immunol (2006) 0.84
PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res Treat (2008) 0.83
Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol (2008) 0.83
d-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified poly(l-lactide) (PLLA) films for localized delivery of paclitaxel. Int J Pharm (2007) 0.83
Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study. MAbs (2010) 0.83